CTRI/2019/03/018136已完成未知
Predictive Value of Circulating Free DNA to assess Clinical Outcome in Patients with Oral Cancer
RMLIMS0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Treatment naive cases with early and
- •locally advanced cancer of oral cavity, confirmed by biopsy ( histopathology will be gold standard for diagnosis).
- •2. Potential candidate for surgery
- •3. Performance status: ECOG 0-2
- •4. Patient consent to be part of study.
排除标准
- •1. Patients having a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated basal or squamous cell carcinoma of skin.
- •2. Metastatic cancer of oral cavity.
- •Performance status: ECOG: >=3.
- •Presence of second malignancy.
- •Patients unwilling to take active treatment or to join the study.
- •A serious co-existing medical condition likely to interfere with lab results including a potentially serious infection.
研究者
相似试验
已完成
不适用
Cell-free DNA as a prognostic biomarker in patients with COVID-19 diseasecfDNA in patients with COVID-19DRKS00031641niversitätsmedizin Mainz72
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
尚未招募
不适用
Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapymalignant tumorJPRN-UMIN000003715Yokohama City University, School of Medicine30
招募中
4 期
The use of donor-derived circulating cell free DNA for early detection of rejection and to modulate immunosuppression following liver transplantation: A randomized controlled trial.CTRI/2023/10/059270Amrita institute of medical sciences and research
尚未招募
不适用
Clinical validation of circulating cell free DNA [ccfDNA] as a biomarker of metabolic healthObesityACTRN12622001326785Commonwealth Scientific and Industrial Research Organisation100